BenevolentAI doses participants in BEN-8744 study
The candidate is a peripherally restricted small-molecule PDE10 inhibitor to treat ulcerative colitis
Read More
Tag: BenevolentAI
Charities link with BenevolentAI to discover new AMD therapies
BenevolentAI has teamed up with Action Against AMD* to find treatments and a potential cure for age-related macular degeneration, the leading cause of blindness in the UK.
Read More
British AI group licenses Janssen drug candidates
British artificial intelligence group BenevolentAI has signed an exclusive license with Johnson & Johnson group Janssen, picking up rights to a series of its novel clinical stage drug candidates.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
